SCHEMBL3206483

SCHEMBL3206483

N=c1n(CCOc2ccccc2)c2ccccc2n1CCc1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
TSHR P16473 3/20 0.63
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
TP53 P04637 3/20 0.58
NPSR1 Q6W5P4 1/20 0.57
ALDH1A1 P00352 3/20 0.56
MITF O75030 1/20 0.56
POLB P06746 1/20 0.49
SLC5A2 P31639 1/20 0.49
ALOX15 P16050 1/20 0.48
HTT P42858 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NPC1 O15118 1/20 0.48
MAPK1 P28482 1/20 0.48
RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3205551 0.89 LMNA (0.67) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL11712251 0.85 LMNA (0.67) LMNASMN1; SMN2TSHRALDH1A1POLB
Bromide SCHEMBL11709807 0.83 LMNA (0.69) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3188073 0.81 SLC5A2 (0.64) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3194234 0.80 LMNA (0.65) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3207909 0.80 TP53 (0.68) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3194997 0.80 LMNA (0.69) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3186754 0.79 TP53 (0.74) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3199285 0.77 LMNA (0.66) LMNASMN1; SMN2TSHRMEN1KMT2A
SCHEMBL3184607 0.77 TSHR (0.64) LMNASMN1; SMN2TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2010-02-11 US disclosed
EP-2041096-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL- CONDUCTANCE CALCIUM-ACTIVATED POTATIUM CHANNELS NeuroSearch AS (DK) 2009-04-01 EP disclosed
WO-2008003752-A1 2 -AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL - CONDUCTANCE CALCIUM -ACT IVATED POTASSIUM CHANNELS NEUROSEARCH A/S (DK) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035951-A1 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 LMNA 2392/4885SMN1; SMN2 3181/4885TSHR 4621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.